Changes in Hong Kong stocks | Pegasus Medical-B (09996) rose more than 5%, reports several core data highlights, and the company raised annual TAVR implantation guidelines

The Zhitong Finance App learned that Peijia Medical-B (09996) rose by more than 5%. As of press release, it had risen 3.14% to HK$5.58, with a turnover of HK$1,252,400.

According to the news, Peijia Healthcare recently revealed its interim results, and many core data are impressive. Total revenue of 425 million yuan was achieved in the first half of the year, an increase of 20.1% over the previous year. Thanks to the combined effect of main revenue growth and refined management, the company's profit quality continued to improve: the company's current gross profit reached 290 million yuan, an increase of 17.1% year on year; both EBITDA and pre-tax profit were positive; net loss for the period narrowed sharply by 87.4% year on year to about 8.99 million yuan, and profit is expected.

It is worth mentioning that during the conference call to release the semi-annual report on August 24, Peijia's management raised the annual implant volume guideline for the company's valve business from the 5000+ units originally anticipated at the beginning of this year to 6000-6,500 units. Among them, the reflux valve business has installed no less than 2,500 units throughout the year, and the revenue growth rate is over 30%, showing the company's strong confidence in the continued growth of the business.